SDGR
NASDAQSchrodinger Inc.
Price$15.34-0.06 (-0.39%)
01:30 PM07:45 PM
News · 26 weeks54+333%
2026-01-182026-07-12
Mix2690d
- Insider11(42%)
- SEC Filings8(31%)
- Other4(15%)
- Earnings2(8%)
- Leadership1(4%)
Latest news
25 items- INSIDEREVP & CFO Jain Rachit sold $13,647 worth of shares (875 units at $15.60) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 50,877 units (SEC Form 4) to cover taxes4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Friesner Richard gifted 679,373 shares and received a gift of 679,373 shares (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- SECSchrodinger Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Schrodinger, Inc. (0001490978) (Filer)
- INSIDERDirector Oberoi Arun was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Chodakewitz Jeffrey was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Friesner Richard was granted 8,141 shares, increasing direct ownership by 1% to 690,365 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Ginsberg Gary L was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Kapeller-Libermann Rosana was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Lynton Michael was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Sender Gary was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Thornberry Nancy was granted 8,141 shares, increasing direct ownership by 47% to 25,388 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- INSIDERDirector Van Kralingen Bridget A was granted 8,141 shares, increasing direct ownership by 71% to 19,640 units (SEC Form 4)4 - Schrodinger, Inc. (0001490978) (Issuer)
- SECSchrodinger Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Schrodinger, Inc. (0001490978) (Filer)
- PRSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Schrödinger, Inc. (NASDAQ:SDGR) today reported that on June 12, 2026, the company granted restricted stock units (RSUs) with respect to 10,771 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs v
- PRThe Quiet Bottleneck in AI Drug Discovery Isn't the Model -- It's the Biology Underneath ItIssued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that is where one Nasdaq-listed company has placed its bet.NEW YORK, June 16, 2026 /CNW/ -- Equity Insider News Commentary — The story the market has been telling itself about artificial intelligence and drug discovery is, at its core, a story about models. Bigger models, smarter models, models that can predict how a protein folds or design an antibody from scratch. But a quieter and increasingly influential argument is taking hold among the people actually
- SECSchrodinger Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - Schrodinger, Inc. (0001490978) (Filer)
- PRSchrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)Schrödinger, Inc. (NASDAQ:SDGR) today reported that on May 18, 2026, the company granted (i) a non-statutory stock option to purchase 1,875 shares of the company's common stock to one newly hired employee and (ii) restricted stock units (RSUs) with respect to 18,766 shares of the company's common stock to seven newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635
- SECSchrodinger Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure8-K - Schrodinger, Inc. (0001490978) (Filer)
- SECSEC Form 10-Q filed by Schrodinger Inc.10-Q - Schrodinger, Inc. (0001490978) (Filer)
- SECSchrodinger Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Schrodinger, Inc. (0001490978) (Filer)
- PRSchrödinger Reports First Quarter 2026 Financial ResultsFirst Quarter ACV of $28 Million, Representing 12% Growth Continued Momentum in Transition to Hosted Software Licensing Schrödinger to Launch Bunsen, an Agentic AI Co-Scientist, This Summer Lilly's Announced $2.3 Billion Acquisition of Ajax Validates Schrödinger's Track Record of High-Value Collaborations Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended March 31, 2026. "Our first quarter results show strong growth in both ACV and drug discovery revenue. ACV growth of 12 percent was driven by usage scale-ups and new deployments; we are also pleased with our progress transitioning customers to hosted licensing. The biopharmaceutical funding env
- PRSchrödinger to Participate in Upcoming Investor ConferencesSchrödinger, Inc. (NASDAQ:SDGR) today announced that management will participate in the following conferences in May: BofA Securities 2026 Healthcare Conference: Fireside chat on Wednesday, May 13, 2026, at 5:20 p.m. E.T. RBC 2026 Global Healthcare Conference: Fireside chat on Tuesday, May 19, 2026 at 2:05 p.m. E.T. The live discussions can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schröd
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Schrodinger Inc.SCHEDULE 13G/A - Schrodinger, Inc. (0001490978) (Subject)
- SECSEC Form DEFA14A filed by Schrodinger Inc.DEFA14A - Schrodinger, Inc. (0001490978) (Filer)
- SECSEC Form DEF 14A filed by Schrodinger Inc.DEF 14A - Schrodinger, Inc. (0001490978) (Filer)
SDGR FAQ
7 questionsWhat does Schrodinger Inc. do?
Schrödinger, Inc. provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates through two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic...Where does SDGR stock trade?
Schrodinger Inc. (SDGR) is listed on NASDAQ.What sector and industry is SDGR in?
Schrodinger Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Schrodinger Inc. go public?
Schrodinger Inc. (SDGR) completed its IPO in 2020.What are analysts saying about SDGR?
Schrodinger Inc. has had 8 recent analyst actions on file. The most recent action was from BofA Securities: Buy with a $2400.00 price target on 2025-12-15. Recent price targets range from $1900.00 to $3800.00.What companies are similar to SDGR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare SDGR side-by-side with any of them on Quantisnow.How can I track SDGR on Quantisnow?
Quantisnow aggregates Schrodinger Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SDGR to receive live email and push alerts on every new disclosure.